Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?

Victor Serebruany, Alex Malinin, Alex Pokov, Umesh Arora, Dan Atar, Dominick Angiolillo

Research output: Contribution to journalArticle

Abstract

Introduction: Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods: We assessed the in vitro effects of preincubation with escalating (12.5-200 ng/mL) concentrations of tirofiban on platelet biomarkers in 20 diabetic patients. Platelet activity was assessed by ADP-, and collagen-induced conventional plasma aggregometry, and by whole blood flow cytometry measuring expression of PECAM-1, GPIb, GP IIb/IIIa antigen and activity, vitronectin, P-selectin, LAMP-1, GP 37, LAMP-3, activated and intact PAR-1 thrombin receptors, GPIV, and platelet-monocyte formation. All patients were treated with aspirin (at least 81 mg daily for 1 month); other antiplatelet agents were not allowed. Results: Significant decrease of ADP-induced platelet aggregation was observed starting at the low 12.5 ng/mL concentration (p = 0.0001), with total inhibition occurring at 50 ng/mL of tirofiban dose. Inhibition of collagen-induced platelet aggregability requires 25 ng/ml of tirofiban (p = 0.002), and was complete at 100 ng/mL. Dose-dependent blockade of GP IIb/IIIa activity was observed with tirofiban concentrations over 50 ng/mL (p = 0.003). Other receptors were unaffected even with the high doses of tirofiban (100-200 ng/mL). Conclusion: Tirofiban completely inhibits ADP- and, with the higher dose, collagen-induced platelet aggregation. Higher loading dose of tirofiban used in the ongoing TENACITY trial (100 ng/mL) may be superior with regard to clinical outcomes to the regimens used in PRISM-PLUS (25 ng/mL), or TARGET (50 ng/mL). Selective inhibition of GPIIb/IIIa activity, and lack of alternative platelet activation beyond the GP IIb/IIIa blockade may represent the therapeutic advantage of tirofiban over other agents.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalThrombosis Research
Volume119
Issue number2
DOIs
StatePublished - 2007

Fingerprint

tirofiban
Platelet Aggregation
Platelet Membrane Glycoprotein IIb
Blood Platelets
Adenosine Diphosphate
Collagen
Platelet Activation
PAR-1 Receptor
CD31 Antigens
Thrombin Receptors
Vitronectin
P-Selectin
Platelet Aggregation Inhibitors
Proxy

Keywords

  • Acute coronary syndrome
  • Diabetes
  • In vitro
  • Platelets
  • Tirofiban

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients : Hitting the TARGET in the TENACITY trial? / Serebruany, Victor; Malinin, Alex; Pokov, Alex; Arora, Umesh; Atar, Dan; Angiolillo, Dominick.

In: Thrombosis Research, Vol. 119, No. 2, 2007, p. 175-181.

Research output: Contribution to journalArticle

Serebruany, Victor ; Malinin, Alex ; Pokov, Alex ; Arora, Umesh ; Atar, Dan ; Angiolillo, Dominick. / Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients : Hitting the TARGET in the TENACITY trial?. In: Thrombosis Research. 2007 ; Vol. 119, No. 2. pp. 175-181.
@article{e1a62cd668074c6d98ff9406d56b5d0f,
title = "Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?",
abstract = "Introduction: Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods: We assessed the in vitro effects of preincubation with escalating (12.5-200 ng/mL) concentrations of tirofiban on platelet biomarkers in 20 diabetic patients. Platelet activity was assessed by ADP-, and collagen-induced conventional plasma aggregometry, and by whole blood flow cytometry measuring expression of PECAM-1, GPIb, GP IIb/IIIa antigen and activity, vitronectin, P-selectin, LAMP-1, GP 37, LAMP-3, activated and intact PAR-1 thrombin receptors, GPIV, and platelet-monocyte formation. All patients were treated with aspirin (at least 81 mg daily for 1 month); other antiplatelet agents were not allowed. Results: Significant decrease of ADP-induced platelet aggregation was observed starting at the low 12.5 ng/mL concentration (p = 0.0001), with total inhibition occurring at 50 ng/mL of tirofiban dose. Inhibition of collagen-induced platelet aggregability requires 25 ng/ml of tirofiban (p = 0.002), and was complete at 100 ng/mL. Dose-dependent blockade of GP IIb/IIIa activity was observed with tirofiban concentrations over 50 ng/mL (p = 0.003). Other receptors were unaffected even with the high doses of tirofiban (100-200 ng/mL). Conclusion: Tirofiban completely inhibits ADP- and, with the higher dose, collagen-induced platelet aggregation. Higher loading dose of tirofiban used in the ongoing TENACITY trial (100 ng/mL) may be superior with regard to clinical outcomes to the regimens used in PRISM-PLUS (25 ng/mL), or TARGET (50 ng/mL). Selective inhibition of GPIIb/IIIa activity, and lack of alternative platelet activation beyond the GP IIb/IIIa blockade may represent the therapeutic advantage of tirofiban over other agents.",
keywords = "Acute coronary syndrome, Diabetes, In vitro, Platelets, Tirofiban",
author = "Victor Serebruany and Alex Malinin and Alex Pokov and Umesh Arora and Dan Atar and Dominick Angiolillo",
year = "2007",
doi = "10.1016/j.thromres.2006.02.004",
language = "English (US)",
volume = "119",
pages = "175--181",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients

T2 - Hitting the TARGET in the TENACITY trial?

AU - Serebruany, Victor

AU - Malinin, Alex

AU - Pokov, Alex

AU - Arora, Umesh

AU - Atar, Dan

AU - Angiolillo, Dominick

PY - 2007

Y1 - 2007

N2 - Introduction: Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods: We assessed the in vitro effects of preincubation with escalating (12.5-200 ng/mL) concentrations of tirofiban on platelet biomarkers in 20 diabetic patients. Platelet activity was assessed by ADP-, and collagen-induced conventional plasma aggregometry, and by whole blood flow cytometry measuring expression of PECAM-1, GPIb, GP IIb/IIIa antigen and activity, vitronectin, P-selectin, LAMP-1, GP 37, LAMP-3, activated and intact PAR-1 thrombin receptors, GPIV, and platelet-monocyte formation. All patients were treated with aspirin (at least 81 mg daily for 1 month); other antiplatelet agents were not allowed. Results: Significant decrease of ADP-induced platelet aggregation was observed starting at the low 12.5 ng/mL concentration (p = 0.0001), with total inhibition occurring at 50 ng/mL of tirofiban dose. Inhibition of collagen-induced platelet aggregability requires 25 ng/ml of tirofiban (p = 0.002), and was complete at 100 ng/mL. Dose-dependent blockade of GP IIb/IIIa activity was observed with tirofiban concentrations over 50 ng/mL (p = 0.003). Other receptors were unaffected even with the high doses of tirofiban (100-200 ng/mL). Conclusion: Tirofiban completely inhibits ADP- and, with the higher dose, collagen-induced platelet aggregation. Higher loading dose of tirofiban used in the ongoing TENACITY trial (100 ng/mL) may be superior with regard to clinical outcomes to the regimens used in PRISM-PLUS (25 ng/mL), or TARGET (50 ng/mL). Selective inhibition of GPIIb/IIIa activity, and lack of alternative platelet activation beyond the GP IIb/IIIa blockade may represent the therapeutic advantage of tirofiban over other agents.

AB - Introduction: Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods: We assessed the in vitro effects of preincubation with escalating (12.5-200 ng/mL) concentrations of tirofiban on platelet biomarkers in 20 diabetic patients. Platelet activity was assessed by ADP-, and collagen-induced conventional plasma aggregometry, and by whole blood flow cytometry measuring expression of PECAM-1, GPIb, GP IIb/IIIa antigen and activity, vitronectin, P-selectin, LAMP-1, GP 37, LAMP-3, activated and intact PAR-1 thrombin receptors, GPIV, and platelet-monocyte formation. All patients were treated with aspirin (at least 81 mg daily for 1 month); other antiplatelet agents were not allowed. Results: Significant decrease of ADP-induced platelet aggregation was observed starting at the low 12.5 ng/mL concentration (p = 0.0001), with total inhibition occurring at 50 ng/mL of tirofiban dose. Inhibition of collagen-induced platelet aggregability requires 25 ng/ml of tirofiban (p = 0.002), and was complete at 100 ng/mL. Dose-dependent blockade of GP IIb/IIIa activity was observed with tirofiban concentrations over 50 ng/mL (p = 0.003). Other receptors were unaffected even with the high doses of tirofiban (100-200 ng/mL). Conclusion: Tirofiban completely inhibits ADP- and, with the higher dose, collagen-induced platelet aggregation. Higher loading dose of tirofiban used in the ongoing TENACITY trial (100 ng/mL) may be superior with regard to clinical outcomes to the regimens used in PRISM-PLUS (25 ng/mL), or TARGET (50 ng/mL). Selective inhibition of GPIIb/IIIa activity, and lack of alternative platelet activation beyond the GP IIb/IIIa blockade may represent the therapeutic advantage of tirofiban over other agents.

KW - Acute coronary syndrome

KW - Diabetes

KW - In vitro

KW - Platelets

KW - Tirofiban

UR - http://www.scopus.com/inward/record.url?scp=33751179864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751179864&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2006.02.004

DO - 10.1016/j.thromres.2006.02.004

M3 - Article

C2 - 16546241

AN - SCOPUS:33751179864

VL - 119

SP - 175

EP - 181

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -